ALMS Alumis Inc. Common Stock

XNAS 6.51 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ALMS $6.51 —
Key stats
$6.51
Pre-market $6.65 +2.15%
52-Week Range
$4.38 – $31.35
YTD
-27.30%
IV Rank (30D)
29.04
Straddle Price
$1.68
P/C Vol Ratio
0.13
Market Cap
$0.9B
Open
$6.81
Day Range
$6.38 – $6.83
Volume
1,119,974
Prev Close
$6.78
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.77
Cost of Equity (CAPM)14.71% (VRP-adj)
WACC14.79%
Volatility Risk Premium+191.0pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.4B
Return on Equity (TTM)-97.1%
Book / Price89.1% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-4187.1%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$11.26 (Market Anchor value)
SMA 20 / Bollinger Mid$6.77
Bollinger Width / SMA20314.6% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: PCRX, PFE, VTRS (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
91%
20-Day Fair Value
≈ by Nov 25, 2026
$6.54
α +0.5% rank 86%
conviction
32%
40-Day Fair Value
≈ by Dec 24, 2026
$6.60
α +1.4% rank 85%
conviction
49%
60-Day Fair Value
≈ by Jan 22, 2027
$6.79
α +4.3% rank 86%
conviction
91%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0% median 11.4× · 3 peers
Peer P/B $11.66 16% median 2.0× · 3 peers
Peer P/S $0.17 16% median 1.9× · 3 peers
Market Anchor (SMA50) $11.26 69% stability 85% (BB-width)
Options Expected (B-L 30d) $6.77 0% 8 strikes · skew +0.14
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.9B
Employees
239
List Date
2024-06-28
CIK
0001847367
Next Earnings
2026-11-12 (After-Close)
EPS Forecast
($0.73) (5 est.)
Headquarters
South San Francisco, CA
Homepage
https://www.alumis.com

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan---9.00%173.70%82.35%
Feb---37.50%12.38%-12.56%
Mar--35.24%-25.87%4.69%
Apr---42.82%8.62%-17.10%
May---8.62%-14.22%-11.42%
Jun0.00%-8.81%38.42%9.87%
Jul-1.91%37.09%6.85%14.01%
Aug0.08%12.35%-16.50%-1.36%
Sep-12.46%-15.11%-21.96%-16.51%
Oct6.09%17.00%-9.71%*4.46%
Nov-18.13%68.20%--25.04%
Dec-4.96%32.79%--13.91%
Total-29.06%25.22%84.87%27.01%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $6.77
SMA 50: $11.26
SMA 200: $21.72
Current: $6.51
EMA 12: $6.71
EMA 26: $7.87
MACD: -1.1525 | Signal: 0.4048
BEARISH
ADX (14): 57.48
STRONG TREND
+DI: 12.83
−DI: 35.83

Momentum Oscillators

RSI (14): 31.51
NEUTRAL
Stoch %K: 53.33
Stoch %D: 57.10
Williams %R: -61.54

Volume & Volatility

BB Upper: $7.50
BB Lower: $6.05
NEUTRAL
OBV: 107,717,132
Vol SMA 20: 1,950,654
Vol ROC: -30.07%
ATR: $0.54
True Range: $0.45
HV 20: 59.0%
HV 30: 62.1%
HV 60: 181.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report - ALMS

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 8/10)

Key Drivers:

  • Positive news sentiment around psoriasis clinical trial pipeline and product developments
  • Strong technical signals from momentum oscillators, including RSI in neutral territory
  • Options market pricing a potential $12.45 move by expiration, indicating high volatility

Primary Risks:

  • High volatility, which may lead to increased market swings
  • Bearish options market sentiment with a put/call volume ratio of 2.80

Investment Thesis: ALMS is poised for continued growth as positive news sentiment around its product pipeline and recent phase 3 data drive momentum. However, high volatility poses a risk that could impact the stock's performance.

Recent News Sentiment Impact: The positive news headlines have contributed to the stock's rally, with the majority of recent articles highlighting the company's advancements in psoriasis treatments.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Bullish
  • Long-term (3-12 months): Neutral

Support/Resistance Levels:

  • Upper Bollinger Band: $29.48
  • Middle Bollinger Band: $26.86
  • Lower Bollinger Band: $24.23

Momentum Signals:

  • RSI: 42.57 (neutral)
  • MACD: Bearish signal with a histogram of -0.10
  • Stochastic %K and %D: Both in neutral territory

Volume Analysis:

  • Volume SMA 20: 909746.04
  • On-Balance Volume (OBV): 152923300.27
  • Volume Rate of Change: -12.29%

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines around ALMS' product pipeline and recent phase 3 data dominate the recent articles.

Sentiment Assessment: Aggregate news sentiment is positive, with a majority of recent articles highlighting the company's advancements in psoriasis treatments.

Catalyst Identification:

  • Upcoming earnings release (no specific date available)
  • Regulatory approvals for Envudeucitinib

Market Narrative: The positive news sentiment around ALMS' product pipeline and recent phase 3 data has driven momentum, aligning with the technical signals from the RSI and Bollinger Bands.

Risk & Volatility Assessment

Beta Interpretation:

  • Beta: 1.34 (vs SPY), indicating high volatility relative to the market

Volatility Regime:

  • Current volatility levels are higher than historical averages, indicating a more volatile regime

Options Market Signals:

  • IV Rank: 69.5% (Medium)
  • Current IV: 214.4%
  • Expected Move: $12.45 (31 DTE), 7-DTE: $4.07
  • Put/Call Volume Ratio: 2.80 (Bearish sentiment)

Downside Protection:

  • Support levels from the Bollinger Bands and momentum oscillators should provide some cushion in case of a pullback.

Market Context & Positioning

Sector Performance:

  • ALMS is outperforming its sector peers, with a relative strength index indicating a strong position within the healthcare sector.

Institutional Activity:

  • Volume patterns suggest institutional interest, with a higher volume flow of calls than puts.

Correlation Analysis:

  • Correlation coefficient: 0.14 (indicating low correlation with the market)

Relative Valuation:

  • ALMS is positioned within its trading range, with potential for further upside if the company continues to deliver positive news and technical signals align.

Key Levels & Action Items

Critical Price Levels:

  • Support levels from the Bollinger Bands: $24.23 and $26.23
  • Resistance level: $29.48 (upper Bollinger Band)

Breakout/Breakdown Levels:

  • Breakout above $29.48 could trigger further upside momentum
  • Breakdown below $24.23 could signal a reversal

Time-Sensitive Catalysts:

  • Earnings release (no specific date available)
  • Regulatory approvals for Envudeucitinib

Risk Management:

  • Set stop-loss levels at $26.23 and consider reducing position size if the stock reaches this level.
  • Monitor volume patterns to gauge institutional interest and potential market swings.

Note: This report is based on the provided data and analysis framework, but it does not constitute buy or sell advice. The reader should consult with their financial advisor before making any investment decisions.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
30.07%
Avg Actual Move
2.82%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-14 Pre-Market 17.38% 1.12% 0.06x Within
2025-08-13 After-Close 72.96% 0.68% 0.01x Within
2025-11-13 After-Close 54.92% 4.55% 0.08x Within
2026-01-09 After-Close 13.42% 7.82% 0.58x Within
2026-03-18 After-Close 13.38% 0.16% 0.01x Within
2026-05-13 After-Close 10.66% 0.93% 0.09x Within
2026-08-12 After-Close 27.79% 4.46% 0.16x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ALMS Options Activity & IV Rank

ALMS IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 111.0%
7-DTE IV: —
Expected Move: $1.68
7-DTE Move: $1.68
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 375
Put Volume: 47
P/C Volume: 0.125
BULLISH
Call OI: 2,375
Put OI: 529
P/C OI: 0.223
Total OI: 2,904

ATM Options Pricing

ATM Call: $0.57
ATM Put: $1.10
Call %: 8.8%
Put %: 16.9%

Chain Summary

Chain Volume: 3,527
Chain OI: 65,821
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 20th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
20%
vs own history
GEX tilt
-0.47
OI-weighted, today
Vanna tilt
-0.50
δ-sensitivity to IV
Charm tilt
+0.25
δ-decay vs time
Vanna tilt -0.50: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 10 ATM contracts, 37k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 115.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)29.0MediumOct 26
Straddle Price (30 DTE)$1.68Oct 26
Beta Analysis

Risk Metrics

Beta: 1.7688
Alpha: 99.39%
Correlation: 0.1652
R-Squared: 2.7%
Stock Volatility: 136.4%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ALMS
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$18.6M
0.01%
#1178 of 3716+8.9%13F
Renaissance Technologies Hedge fund
Jim Simons
$657K
0.00%
#2498 of 3138-69.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ALMS Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 97,706,351 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

201 filers125,546,470 shares$3.40B value128.49% of float
# Filer Shares Value % of Total % of Float Period
1 AyurMaya Capital Management Company, LP 15,139,707 $426.03M 12.52% 15.50% 2026-06-30
2 BlackRock, Inc. Custodian 8,218,151 $231.26M 6.79% 8.41% 2026-06-30
3 FMR LLC Custodian 6,769,170 $190.48M 5.60% 6.93% 2026-06-30
4 Deep Track Capital, LP 6,348,558 $178.65M 5.25% 6.50% 2026-06-30
5 Samsara BioCapital, LLC 6,345,219 $178.55M 5.25% 6.49% 2026-06-30
6 Foresite Capital Management V, LLC 5,896,995 $165.94M 4.88% 6.04% 2026-06-30
7 T. Rowe Price Associates, Inc. 5,199,838 $146.32M 4.30% 5.32% 2026-06-30
8 venBio Partners LLC 4,528,408 $127.43M 3.74% 4.63% 2026-06-30
9 Foresite Capital Management VI LLC 4,247,670 $119.53M 3.51% 4.35% 2026-06-30
10 Vanguard Capital Management LLC 4,215,703 $118.63M 3.49% 4.31% 2026-06-30
11 Nextech Invest Ltd. 3,540,998 $99.64M 2.93% 3.62% 2026-06-30
12 Cormorant Asset Management, LP 3,285,596 $92.46M 2.72% 3.36% 2026-06-30
13 Saturn V Capital Management LP 2,915,443 $82.04M 2.41% 2.98% 2026-06-30
14 Octagon Capital Advisors LP 2,830,700 $79.66M 2.34% 2.90% 2026-06-30
15 Jupiter Topco LLC 2,355,122 $66.24M 1.95% 2.41% 2026-06-30
16 State Street Corp 2,187,266 $61.55M 1.81% 2.24% 2026-06-30
17 Geode Capital Management, LLC Custodian 2,168,517 $61.03M 1.79% 2.22% 2026-06-30
18 MPM BioImpact LLC 2,019,020 $56.82M 1.67% 2.07% 2026-06-30
19 BAKER BROS. ADVISORS LP 2,012,500 $56.63M 1.66% 2.06% 2026-06-30
20 SR One Capital Management, LP 1,959,896 $55.15M 1.62% 2.01% 2026-06-30
21 Janus Henderson Group plc 2,124,408 $46.79M 1.37% 2.17% 2026-03-31
22 Vanguard Group Inc Custodian 4,103,290 $40.05M 1.18% 4.20% 2025-12-31
23 Invesco Ltd. Custodian 1,173,518 $33.02M 0.97% 1.20% 2026-06-30
24 Novo Holdings A/S 1,100,000 $30.95M 0.91% 1.13% 2026-06-30
25 Principal Financial Group, Inc. 1,068,060 $30.06M 0.88% 1.09% 2026-06-30
11 filers$27.31M notional
# Filer Notional Value % of Total Period
1 Ikarian Capital, LLC $10.03M 36.71% 2026-06-30
2 DIADEMA PARTNERS LP $5.63M 20.61% 2026-06-30
3 BOOTHBAY FUND MANAGEMENT, LLC $2.94M 10.78% 2026-06-30
4 Caption Management, LLC $2.81M 10.30% 2026-06-30
5 Susquehanna International Group, LLP Custodian $2.49M 9.12% 2026-06-30
6 Citadel Advisors LLC Custodian $1.58M 5.79% 2026-06-30
7 Jane Street Group, LLC Custodian $680.99K 2.49% 2026-06-30
8 Persistent Asset Partners Ltd $443.67K 1.62% 2026-06-30
9 Point72 Asset Management, L.P. $343.31K 1.26% 2026-06-30
10 Simplex Trading, LLC Custodian $202.61K 0.74% 2026-06-30
11 GROUP ONE TRADING LLC Custodian $157.58K 0.58% 2026-06-30
7 filers$5.24M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $2.04M 38.93% 2026-06-30
2 Citadel Advisors LLC Custodian $1.22M 23.36% 2026-06-30
3 Jane Street Group, LLC Custodian $1.14M 21.70% 2026-06-30
4 Simplex Trading, LLC Custodian $377.08K 7.20% 2026-06-30
5 Point72 Asset Management, L.P. $343.31K 6.55% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $118.19K 2.26% 2026-06-30
7 HAP TRADING, LLC $272 <0.01% 2025-09-30

ALMS Insider Trading (Form 4)

Latest: 2026-09-09
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-09 Srinivas Akkaraju Director Mixed +890,590 $10.84 $9.71M EDGAR
2026-08-05 Sanam Pangali Chief Legal Officer Sell (S) −1,364 $26.37 -$36.0K EDGAR
2026-08-05 Roy C. Hardiman Chief Business & Strategy Ofcr Sell (S) −2,692 $26.37 -$71.0K EDGAR
2026-08-05 John R. Schroer Chief Financial Officer Sell (S) −3,282 $26.37 -$86.5K EDGAR
2026-08-05 Jorn Drappa Chief Medical Officer Sell (S) −2,447 $26.37 -$64.5K EDGAR
2026-08-05 Mark Christopher Bradley Chief Development Officer Sell (S) −2,572 $26.37 -$67.8K EDGAR
2026-08-05 David M Goldstein Chief Scientific Officer Sell (S) −2,596 $26.37 -$68.5K EDGAR
2026-07-08 Sanam Pangali Chief Legal Officer Mixed — $16.53 -$114.7K EDGAR
2026-07-02 Srinivas Akkaraju Director Award (A) +3,553 — EDGAR
2026-07-02 Zhengbin Yao Director Award (A) +3,553 — EDGAR
2026-07-02 Sapna Srivastava Director Award (A) +3,553 — EDGAR
2026-07-02 Patrick Machado Director Award (A) +3,553 — EDGAR
2026-07-02 Lynn A. Tetrault Director Award (A) +3,553 — EDGAR
2026-05-27 Jorn Drappa Chief Medical Officer Exer (M) +26,852 $6.65 $178.6K EDGAR
2026-04-03 James B. Tananbaum Director Other (J) −495,984 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ALMS Insider Holdings

24 insiders · @ $6.51
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 David E. Goel Director 15,139,707 $98.56M $0 1 2025-05-23
2 Srinivas Akkaraju Director 4,667,288 $30.38M $55.26M 14 2026-09-09
3 James B. Tananbaum Director 4,247,670 $27.65M $50.83M 6 2026-04-03
4 Foresite Labs Fund I, L.P. 10%+ Owner 2,614,215 $17.02M $4.80M 1 2025-11-25
5 Foresite Labs Affiliates 2021, LLC 10%+ Owner 2,542,003 $16.55M $86.19M 2 2025-11-19
6 Foresite Capital Opportunity Management V, LLC 10%+ Owner 2,542,003 $16.55M $27.85M 1 2025-11-19
7 Foresite Labs, LLC 10%+ Owner 1,960,337 $12.76M $15.47M 4 2026-04-03
8 Foresite Capital Opportunity Fund V, L.P. 10%+ Owner 1,960,337 $12.76M $0 1 2026-04-03
9 Foresite Capital Fund VI LP 10%+ Owner 1,176,470 $7.66M $1.82M 1 2025-05-06
10 Foresite Capital Fund V, L.P. 10%+ Owner 1,176,470 $7.66M $423.00M 2 2026-01-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ALMS Board & Officers

As of SEC filings through Sep 9, 2026

Directors 9

Officers 8

10% owners 14

Changes in the last 10 years (34)
Jul 4, 2025Sanam Pangali became Chief Legal Officer
May 21, 2025Lynn A. Tetrault became a director
Feb 20, 2025Roy C. Hardiman listed as Chief Business & Strategy Ofcr (previously Chief Business & Legal Officer) in SEC filings
Jun 27, 2024Zhengbin Yao became a director
Jun 27, 2024Srinivas Akkaraju became a director
Jun 27, 2024Sara Klein became General Counsel - Corp Secy
Jun 27, 2024Sapna Srivastava became a director
Jun 27, 2024Roy C. Hardiman became Chief Business & Legal Officer
Jun 27, 2024Patrick Machado became a director
Jun 27, 2024Martin Babler became a director
Jun 27, 2024Martin Babler became President, CEO and Chairman
Jun 27, 2024Mark Christopher Bradley became Chief Development Officer
Jun 27, 2024Labs Co-Invest V, LLC became a 10% owner
Jun 27, 2024Jorn Drappa became Chief Medical Officer
Jun 27, 2024John R. Schroer became Chief Financial Officer
Jun 27, 2024James B. Tananbaum became a director
Jun 27, 2024James B. Tananbaum became a 10% owner
Jun 27, 2024Foresite Labs, LLC became a 10% owner
Jun 27, 2024Foresite Labs Management I, LLC became a 10% owner
Jun 27, 2024Foresite Labs Fund I, L.P. became a 10% owner
Not reported recently (2)
  • Alan Colowick · Last reported as a director in an SEC filing dated Apr 3, 2025
  • Sara Klein · Last reported as General Counsel - Corp Secy in an SEC filing dated Feb 20, 2025
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ALMS Proposed Insider Sales (Form 144)

Latest: 2026-07-06
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-07-06 SANAMPREET PANGALI Officer 5,000 $140.0K 2026-07-06 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
59 ETFs hold ALMS
25 shown · $100.03M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $23.3M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $13.4M $74.6B 2026-10-23
3 SCHA Schwab U.S. Small-Cap ETF Nport 0.04% $8.4M — 2026-05-31
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $7.5M — 2026-09-30
5 XPH State Street® SPDR® S&P® Pharmaceuticals ETF SPDR (State Street) 1.43% $6.3M $439.0M 2026-10-23
6 TMSL T. Rowe Price Small-Mid Cap ETF Nport 0.19% $5.1M — 2026-06-30
7 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.04% $5.0M $13.7B 2026-10-23
8 IBB iShares Biotechnology ETF iShares (BlackRock) 0.05% $5.0M $10.7B 2026-10-23
9 USVM VictoryShares US Small Mid Cap Value Momentum ETF Nport 0.20% $3.5M — 2026-06-30
10 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $3.4M — 2026-09-30
11 DWAS Invesco Dorsey Wright SmallCap Momentum ETF Nport 0.68% $2.8M — 2026-05-31
12 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.10% $2.8M — 2026-07-31
13 IHE iShares U.S. Pharmaceuticals ETF iShares (BlackRock) 0.13% $2.1M $1.5B 2026-10-23
14 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.13% $1.9M — 2026-07-31
15 NUSC Nuveen ESG Small-Cap ETF Nport 0.14% $1.9M — 2026-07-31
16 VHT Vanguard Health Care ETF Vanguard 0.01% $1.3M — 2026-09-30
17 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $1.0M — 2026-05-31
18 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $865,643 — 2026-10-23
19 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.04% $825,526 — 2026-10-23
20 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $794,935 — 2026-10-23
21 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $770,622 $96.5B 2026-10-23
22 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $756,390 — 2026-10-23
23 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.04% $630,389 — 2026-09-30
24 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.04% $407,702 $1.0B 2026-10-23
25 ESML iShares ESG Aware MSCI USA Small-Cap ETF iShares (BlackRock) 0.01% $402,325 $2.7B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.97
TTM Revenue
$8.40M
TTM Net Income
$-237.40M
TTM Op. Cash Flow
$-376.25M
Quarterly figures (8 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$1.74M$-93.05M$-0.74$-87.08M
Q4 '252025-12-31$1.93M$-93.12M$-0.94$-71.91M
Q3 '252025-09-30$2.07M$-110.54M$-1.06$-110.91M
Q2 '252025-06-30$2.67M$59.32M$0.77$-106.35M
Q1 '252025-03-31$17.39M$-98.96M$-1.82$-80.36M
Q4 '242024-12-31—$-94.90M$-0.23$-74.76M
Q3 '242024-09-30—$-92.98M$-1.73$-83.77M
Q2 '242024-06-30—$-56.51M$-23.10$-52.29M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-14
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.12
P/S
75.70
EV/EBITDA
—
EV/Sales
68.10
ROE
-41.9%
ROA
-35.3%
Div Yield
0.00%
FCF Yield
-59.15%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$636.07M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
10.30M
SI % of Float
13.82%
Days to Cover
3.59
Short Vol Ratio
39.7%
Free Float
74.49M
Float %
60.4%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-15